Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 14 clients • 17 examiners • 11 art units • 0 of 17 (0%) have an AI response strategy ready
Juniv LLP operates in Biotechnology & Pharmaceuticals. It has 260 career applications. The firm has a resolved allowance rate of 77.08 percent. It averages 3.32 office actions per allowance. There are 15 pending office actions.
The 77.08 percent allowance rate is the result of its 260 career applications. The average of 3.32 office actions per allowance reflects the typical interaction with the patent office. The 15 pending office actions show the current volume of active prosecution in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 5 (29%) |
| Double-patenting + other | 8 (47%) |
| Multi-statute (no §101) | 3 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| MOEHLMAN, ANDREW TERRY | 1 | 66.3% | +61.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | CANDELARIA, JULIANA IRENE | — |
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BRAUN, MADELINE E | — |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
| 18505975 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | FOWLER, ALAN JEROME | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | MCKNIGHT, CIARA A | 13d |
| 18813917 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | MOU, LIYUAN | — |
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BRAUN, MADELINE E | — |
| 18732637 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | LEE, ANDREW P | — |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | FAUST, AMBER KATHLEEN | — |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1655 | 1 |
| 1624 | 1 |
| 1691 | 1 |
| 1656 | 1 |
| 1616 | 1 |
| 1644 | 1 |
| 1622 | 1 |
| 1641 | 1 |
| 1628 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | Carsgen Therapeutics Co., Ltd. | CANDELARIA, JULIANA IRENE | §102§103§112DP | Non-Final OA | — | Pending | Oct 07, 2024 | |
| 18813917 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | MOU, LIYUAN | §103§112DP | Non-Final OA | — | Pending | Aug 23, 2024 | |
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Ic-Medtech Corp. | BRAUN, MADELINE E | §102§112 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18732637 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | Ic-Medtech Corp. | LEE, ANDREW P | §103 | Non-Final OA | — | Pending | Jun 04, 2024 | |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | Sichuan Real&Best Biotech Co., Ltd. | MOEHLMAN, ANDREW TERRY | 1655 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | Sinomab Bioscience Limited | FAUST, AMBER KATHLEEN | §102§103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 | |
| 18505975 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NucMito Pharmaceuticals Co., Ltd. | FOWLER, ALAN JEROME | 1691 | §102§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | Numaferm GmbH | MCKNIGHT, CIARA A | 1656 | §102DP | Final Rejection | 13d | Pending | Sep 17, 2023 |
| 18253455 | DRY POWDER ANTIVIRAL COMPOSITIONS AND THEIR USE FOR TREATING VIRAL INFECTION | Nano Pharmasolutions, Inc. | SAEED, ALI S | 1616 | §102§103DP | Final Rejection | — | Pending | May 18, 2023 |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Non-Final OA | 12d | Pending | Mar 13, 2023 |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | Crage Medical Co., Limited | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 393d overdue | Pending | Feb 24, 2023 |
| 17999843 | BIARYLSULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING FIBROTIC LUNG DISEASE | NovoMedix, LLC | WELLS, LAUREN QUINLAN | 1622 | §103DP | Non-Final OA | 13d | Pending | Nov 23, 2022 |
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | Cure Genetics Co., Limited | DIBRINO, MARIANNE | 1641 | §102§112DPOther | Final Rejection | 70d overdue | Pending | Nov 09, 2022 |
| 17963504 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA | Health Hope Pharma Hk Limited | BARSKY, JARED | 1628 | §103 | Final Rejection | 87d overdue | Pending | Oct 11, 2022 |
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | Carsgen Life Sciences Co., Ltd. | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 4d overdue | Pending | Dec 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial